Indivior Pharmaceuticals, Inc.
About
Indivior Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 24 2026
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
Apr 9 2026
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
Apr 9 2026
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
Mar 31 2026
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
Mar 17 2026
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder